Shut-down Baltimore vaccine plant cleared to return to operation by FDA

Emergent BioSolutions' Baltimore plant will reopen soon after the FDA forced a shut down in April. Plant forced to close after Johnson & Johnson vaccines were contaminated with AstraZeneca vaccine ingredients. Further investigation found unsanitary conditions and that workers were not properly trained. Once opened, the factory could produce up to 120 million vaccine doses every month